^
    Back
    Association details:
    Biomarker:NRG1 fusion
    Cancer:Ovarian Cancer
    Drug:seribantumab (MM-121) (HER3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

    Excerpt:
    ...- Locally-advanced or metastatic solid tumor with an NRG1 gene fusion identified through molecular assays, such as PCR, NGS (RNA or DNA) or FISH, by a CLIA-certified or similarly accredited laboratory...
    Trial ID:
    CRESTONE
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Elevation Oncology Press Release
    Title:

    Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

    Published date:
    10/26/2020
    Excerpt:
    Elevation Oncology...announced today the presentation of preclinical data on the specific inhibition of NRG1 fusion signaling by seribantumab... in patient derived xenograft models of ovarian and lung cancer that express an NRG1 gene fusion, seribantumab reduced tumor volume following treatment at clinically relevant doses.